Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis

doi:10.3748/wjg.v30.i13.1871

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3890)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-4) series.

Item

Count

PDF

HTML

2728

Figures (1-9)

241

Tables (1-4)

229

Sum=3273

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

135

Download

282

Sum=417

Apr 7, 2024 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 7, 2024; 30(13): 1871-1886
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1871

Full Size Figure Download Figure

Figure 4 Cumulative persistence rate of tofacitinib administration. A: Overall cumulative persistence rate of tofacitinib administration; B: Cumulative persistence rate of tofacitinib administration according to partial Mayo Score (pMS) at baseline (Group 1: pMS 3-4, Group 2: pMS 5–6, Group 3: pMS 7–9); C: Cumulative persistence rate of tofacitinib administration between patients who were classified as in clinical remission or non-clinical remission at week 8. pMS: Partial Mayo Score.

Citation: Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World J Gastroenterol 2024; 30(13): 1871-1886
URL: https://www.wjgnet.com/1007-9327/full/v30/i13/1871.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i13.1871